NCT03520686Phase 3Terminated

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Study sponsor: ImmunityBio, Inc. · IBRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-10-13Actual
Enrollment · participants102Actual
Source updated2026-05-26Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 1538 participants (planned). After: 102 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 31 Oct 2026. After: 13 Oct 2025.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview